PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 60 | 4 | 719-724
Article title

Antibiotics sensitivity of Candida clinical and food-borne isolates

Content
Title variants
Languages of publication
EN
Abstracts
EN
Candida is a yeast species recognized as the most frequent etiological agent of systemic and invasive thrush in humans. Invasions can affect all tissues, organs and systems of human in various stages of development. In the last 10 years Candida infections have increased 15 times. The purpose of our study was to determine the sensitivity of four antibiotics belonging to three different groups of antifungal agents against clinical and food-borne Candida strains. Our studies showed that of all tested strains, 7% was resistant to nystatin, 32% to fluconazole, 23% to voriconazole, and no strains grew in the presence of caspofungin. Despite the differences in biochemical profiles of clinical and food-borne isolates of Candida, a group of strains showing resistance to antibiotics include both types of isolates. At the same time circulating of antibiotic-resistant strains outside the hospital environment and the yeast infection via food is possible.
Publisher

Year
Volume
60
Issue
4
Pages
719-724
Physical description
Dates
published
2013
received
2013-10-31
revised
2013-12-04
accepted
2013-12-17
Contributors
  • Department of Biotechnology and Food Science, Institute of Fermentation Technology and Microbiology, Lodz University of Technology, Łódź, Poland
  • Department of Biotechnology and Food Science, Institute of Fermentation Technology and Microbiology, Lodz University of Technology, Łódź, Poland
  • Department of Biotechnology and Food Science, Institute of Fermentation Technology and Microbiology, Lodz University of Technology, Łódź, Poland
  • Department of Intensive Care and Congenital Newborn and Infants, Polish Mother's Memorial Hospital Research Institute, Łódź, Poland
References
  • Al-Badriyeh D, Liew D, Stewart K, Kong DC (2012) Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses 55: 244-256.
  • Barăo de Aguiar MMG, Pereira de Albuquerque R, Marinho DS, Braga DRS, Dornelas CB, Oliveira A, Pereira de Sousa V, Torres SR, Alviano DS, Alviano CS, Cabral LM, Holandino C (2010) Oral sustained release nystatin tablets for the treatment of oral candidiasis: formulation development and validation of UV spectrophotometric analytical methodology for content determination. Drug Dev Ind Pharm 36: 594-600.
  • Bajpai VK, Kang SC, Park E, Jeon WT, Baek KH (2011) Diverse role of microbially bioconverted product of cabbage (Brassica oleracea) by Pseudomonas syringe pv. T1 on inhibiting Candida species. Food Chem Toxicol 49: 403-407.
  • Chandrasekar P (2011) Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother 66: 457-65.
  • Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Salvado M, Warnock DW, Pahissa A, Rodriguez-Tudela JL; Barcelona Candidemia Project Study Group (2005) In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55: 194-199.
  • Deptuła A, Gospodarek E (2010) Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains. Arch Microbiol 192: 79-84.
  • Dominguez-Gil A, Martin I, Garcia Vargas M (2007) Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig 27: 197-205.
  • Dzierżanowska D (2001) Antybiotykoterapia praktyczna. A-Medica Press, Bielsko Biała, Polska (in Polish).
  • Finkelman MA (2010) Pneumocystis jiroveci infection: cell wall (1-3)-β-D-glucan biology and diagnostic utility. Crit Rev Microbiol 36: 271-281.
  • Hossain MA, Maesaki S, Razzaque MS, Tomono K, Taguchi T, Kohno S (2000) Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating nystatin. J Antimicrob Chemother 46: 263-268.
  • Ibanez-Nolla J, Nolla-Salas M, Leon M (2004) Early diagnosis of candidiasis in non-neutropenic critically ill patients. J Infect 48: 181-192.
  • Kaufman G (2011) Antibiotics: mode of action and mechanisms of resistance. Nursing Standard 25: 49-55.
  • Kennedy MJ, Wolz PA (2007) Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun 49: 654-663.
  • Kostecka M (2011) Kandydoza przewodu pokarmowego u osób leczonych antybiotykami - profilaktyczne stosowanie suplementów diety. Mikol Lek 18: 11-14 (in Polish).
  • Kuźma Ł, Różalski M, Walencka E, Różalska B, Wysokińska H (2007) Antimicrobial activity of diterpenoids from hairy roots of Salvia sclarea L.: Salvipisone as a potential anti-biofilm agent active against antibiotic resistant Staphylococci. Phytomedicine 14: 31-35.
  • Lewis K, Ausubel FM (2006) Prospects for plant-derived antibacterials. Nat Biotechnol 24: 1504-1507.
  • Lobo ML, Esteves F, Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O (2013) Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia: a pilot study in mice. PLOS ONE 8: e70619.
  • Marchettia O, Cordonnierb C, Calandraa T (2007) Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. EJC 5: 32-42.
  • McCormack PL, Perry CM (2005) Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65: 2049-2068.
  • Ng AW, Wasan KM, Lopez-Berestein G (2003) Development of liposomal polyene antibiotics: a historical perspective. J Pharm Pharm Sci 6: 67-83.
  • Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA (2006) Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 44: 1740-1743.
  • Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ (2003) Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program. Clin Microbiol 41: 1440-1446.
  • Semis R, Nili SS, Munitz A, Zaslavsky Z, Polacheck I, Segal E (2012) Pharmacokinetics, tissue distribution and immunomodulatory effect of intralipid formulation of nystatin in mice. J Antimicrob Chemother 67: 1716-1721.
  • Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo A (2012) Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. Microbiol Rev 36: 288-305.
  • Spellberg BJ, Filler SG, Edwards JE (2006) Current treatment strategies for disseminated candidiasis. Clin Infec Dis 42: 244-251.
  • Straus SK, Hancock RE (2006) Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Acta Biochim Biophys 1758: 1215-1223.
  • Szczepaniak W, Zawirska A, Adamski Z (200) Rola grzybów drożdżopodobnych rodzaju Candida w etiopatogenezie wybranych schorzeń przewodu pokarmowego. Nowiny Lek 73: 475-478 (in Polish).
  • Szymankiewicz M, Dancewicz M (2008) Aktywność in vitro worikonazolu i kaspofunginy wobec szczepów Candida spp. oceniana metodą Etestu. Mikol Lek 15: 13-15 (in Polish).
  • Torba DH, Lika M, Sinani F (2012) Fungi frequence of Candida genus at the pulmonary patents, their identification and characterization. Albanian J Agric Sci 11: 2218-2020.
  • Tornai-Lehoczki J, Péter G, Dlauchy D (2003) CHROMagar Candida medium as a practical tool for the differentiation and presumptive identification of yeast species isolated from salads. Int J Food Microbiol 86: 189-200.
  • Tunca R, Tolga GV, Haziroúlu G, Ataseven L, Zen H, Toplu N (2006) Pathological and immunohistochemical investigation of naturally occurring systemic Candida albicans infection in dogs. Turk J Vet Anim Sci 30: 545-551.
  • Tyrer H, Ainsworth P, Ibanoglu S, Bozkurt H (2004) Modelling the growth of Pseudomonas fluorescens and Candida sake in ready-to-eat meals. J Food Eng 65: 137-143.
  • Wieczorek P, Sacha P, Żórawski M, Jakoniuk P, Tryniszewska E (2008) Aktywność in vitro kaspofunginy wobec szczepów z rodzaju Candida. Mikol Lek 15: 135-139 (in Polish).
  • Wiederhold NP, Herrera LA (2012) Caspofungin for the treatment of immunocompromised and severely Ill children and neonates with invasive fungal infections. Clin Med Insights: Pediatr 6: 19-31.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv60p719kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.